Chemfab Alkalis Ltd Board Approves Q3 FY26 Unaudited Financial Results
Chemfab Alkalis Limited's Board approved Q3 FY26 results. Standalone revenue was ₹21,983.99 lakhs with a net loss of ₹103.80 lakhs. Consolidated revenue was ₹23,670.93 lakhs with a net profit of ₹7.07 lakhs for the nine months ended Dec 31, 2025. 10,000 ESOP shares were allotted.
The announcement pertains to the quarterly financial results, which are material information for investors. The results show a loss on standalone and a profit on consolidated basis, which will influence investor decisions.
The announcement reports financial results which show a mixed performance with a loss on standalone basis and a small profit on consolidated basis. No significant positive or negative catalysts were highlighted.
Chemfab Alkalis Limited announced the outcome of its Board Meeting held on January 28, 2026. The Board approved the Un-Audited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025. The meeting commenced at 2:00 P.M. and concluded at 5:00 P.M. The financial results were recommended by the Audit Committee prior to their approval by the Board.
The financial statements indicate that for the nine months ended December 31, 2025, the standalone revenue from operations was ₹21,983.99 lakhs, with a net loss after tax of ₹103.80 lakhs. The consolidated revenue from operations for the same period was ₹23,670.93 lakhs, with a net profit after tax of ₹7.07 lakhs.
During the nine months ended December 31, 2025, the company allotted 10,000 Equity shares under its Employee Stock Option Scheme "CAESOS 2020". Additionally, the company noted the consolidation of labor laws into four codes by the Government of India, effective November 21, 2025. The incremental impact of these changes on the financial results was assessed as immaterial.
What to do with a filing like this
Chemfab Alkalis Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Chemfab Alkalis Limited. Read the original for the full detail.